# A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus

> **NCT03338010** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 536 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** LY2963016
- **DRUG:** Lantus®

## Key facts

- **NCT ID:** NCT03338010
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-22
- **Primary completion:** 2020-03-18
- **Final completion:** 2020-03-18
- **Target enrollment:** 536 (ACTUAL)
- **Last updated:** 2021-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03338010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03338010, "A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 2 Diabetes Mellitus". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03338010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*